Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Mol Cell Proteomics. 2024 Jan 19:100721. doi: 10.1016/j.mcpro.2024.100721. Online ahead of print.
ABSTRACT
Alzheimer’s disease (AD) is characterised by several neuropathological changes, mainly extracellular amyloid aggregates (plaques), intraneuronal inclusions of phosphorylated tau (tangles), as well as neuronal and synaptic degeneration, accompanied by tissue reactions to these processes (astrocytosis and microglial activation) that precede neuronal network disturbances in the symptomatic phase of the disease. A number of biomarkers for these brain tissue changes have been developed, mainly using immunoassays. In this review, we discuss how targeted mass spectrometry (TMS) can be used to validate and further characterize classes of biomarkers reflecting different AD pathologies, such as tau- and amyloid-beta pathologies, synaptic dysfunction, lysosomal dysregulation, and axonal damage, and the prospect of using TMS to measure these proteins in clinical research and diagnosis. TMS advantages and disadvantages in relation to immunoassays are discussed, and complementary aspects of the technologies are discussed.
PMID:38246483 | DOI:10.1016/j.mcpro.2024.100721
![Google](https://www.google.com/images/branding/googlelogo/2x/googlelogo_light_color_92x30dp.png)
![Google Keep](https://www.gstatic.com/images/branding/product/1x/keep_48dp.png)
![Share on Linkedin](https://psychiatryai.com/wp-content/uploads/2023/10/linkedin-logo-png-2048-1.png)
Estimated reading time: 3 minute(s)
Latest: Psychiatryai.com #RAISR4D Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Cool Evidence: Engaging Young People and Students in Real-World Evidence
![](/wp-content/uploads/2024/04/bd462cc11bcf0bd0d0d6f1d0f8b7cd04-modified-1.png)
Real-Time Evidence Search [Psychiatry]
![](/wp-content/uploads/2024/04/pubmed.png)
AI Research
![](/wp-content/uploads/2024/05/Il5nR_nf_400x400-modified-1.png)
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
🌐 90 Days
AI Virtual Reality Related Evidence Matrix
An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease Genomic stress and impaired DNA repair in Alzheimer disease Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer's disease mouse model, as revealed by spatial transcriptomics Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles Co-registration of MALDI-MSI and histology demonstrates gangliosides co-localize with amyloid beta plaques in Alzheimer's disease Co-registration of MALDI-MSI and histology demonstrates gangliosides co-localize with amyloid beta plaques in Alzheimer's disease Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance In situ seeding assay: A novel technique for direct tissue localization of bioactive tau Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change Towards cascading genetic risk in Alzheimer's disease Personalized whole-brain neural mass models reveal combined Ab and tau hyperexcitable influences in Alzheimer's disease Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer's disease and a history of traumatic brain injury Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease Resiliency to Alzheimer's disease neuropathology can be distinguished from dementia using cortical astrogliosis imaging P2Y1 receptor in Alzheimer's disease Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer's disease Characterization of reduced astrocyte creatine kinase levels in Alzheimer's disease Modern neurophysiological techniques indexing normal or abnormal brain aging Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers Effects of time of the day at sampling on CSF and plasma levels of Alzheimer' disease biomarkers Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup Thermal evaporation as sample preparation for silver-assisted laser desorption/ionization mass spectrometry imaging of cholesterol in amyloid tissues Proximity extension assay in cerebrospinal fluid identifies neurofilament light chain as biomarker of neurodegeneration in sporadic cerebral amyloid angiopathy Single-extracellular vesicle (EV) analyses validate the use of L1 Cell Adhesion Molecule (L1CAM) as a reliable biomarker of neuron-derived EVs Evidence for a novel neuronal mechanism driving Alzheimer's disease, upstream of amyloid Extracellular ATP is a homeostatic messenger that mediates cell‒cell communication in physiological processes and psychiatric diseases Extracellular ATP is a homeostatic messenger that mediates cell‒cell communication in physiological processes and psychiatric diseases Evaluation of altered cell-cell communication between glia and neurons in the hippocampus of 3xTg-AD mice at two time points Hypoglycemia and Alzheimer Disease Risk: The Possible Role of Dasiglucagon Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review Utilization of fluid-based biomarkers as endpoints in disease-modifying clinical trials for Alzheimer's disease: a systematic review The complexity of extracellular vesicles: Bridging the gap between cellular communication and neuropathology G-protein coupled estrogen receptor 1, amyloid-β, and tau tangles in older adults A new angle on transcranial magnetic stimulation coil orientation: A targeted narrative review Regulation of cell distancing in peri-plaque glial nets by Plexin-B1 affects glial activation and amyloid compaction in Alzheimer's disease Central nervous system-derived extracellular vesicles: the next generation of neural circulating biomarkers? Post-GWAS multiomic functional investigation of the TNIP1 locus in Alzheimer's disease highlights a potential role for GPX3 Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation Inflammasomes in chronic liver disease: hepatic injury, fibrosis progression and systemic inflammation Amino-terminally elongated Aβ peptides are generated by the secreted metalloprotease ADAMTS4 and deposit in a subset of Alzheimer's disease brains Biomarkers of Alzheimer's Disease Associated with Programmed Cell Death Reveal Four Repurposed Drugs Associations among plasma, MRI, and amyloid PET biomarkers of Alzheimer's disease and related dementias and the impact of health-related comorbidities in a community-dwelling cohort Altering plasma lipids and liver enzyme activities via hippocampal injections of hen Lysozyme amyloid aggregates in an Alzheimer's disease mouse model: Insights into the therapeutic role of Bis (Indolyl) phenylmethane Systemic inflammation in Ab1-40-induced Alzheimer's disease model: New translational opportunities Innate immune activation in neurodegenerative diseases Proteomic Profiling of Samples Derived from a Murine Model Following Cryptococcus neoformans Infection Cannabidiol protects mouse hippocampal neurons from neurotoxicity induced by amyloid β-peptide25-35 D-peptide-magnetic nanoparticles fragment tau fibrils and rescue behavioral deficits in a mouse model of Alzheimer's disease Application of omics in the diagnosis, prognosis, and treatment of acute myeloid leukemia The vascular contribution of apolipoprotein E to Alzheimer's disease A cross-sectional study of α-synuclein seed amplification assay in Alzheimer's disease neuroimaging initiative: Prevalence and associations with Alzheimer's disease biomarkers and cognitive function Autophagy preferentially degrades non-fibrillar polyQ aggregates Selection of lansoprazole from an FDA-approved drug library to inhibit the Alzheimer's disease seed-dependent formation of tau aggregates Alterations of human CSF and serum-based mitophagy biomarkers in the continuum of Alzheimer disease Relationship of plasma biomarkers to digital cognitive tests in Alzheimer's disease Alzheimer blood biomarkers: practical guidelines for study design, sample collection, processing, biobanking, measurement and result reporting Comparison of tau spread in people with Down syndrome versus autosomal-dominant Alzheimer's disease: a cross-sectional study PPARs (Peroxisome Proliferator-activated Receptors) and Their Agonists in Alzheimer's Disease
Evidence Blueprint
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
☊ AI-Driven Related Evidence Nodes
(recent articles with at least 5 words in title)
More Evidence
![](https://psychiatryai.com/wp-content/uploads/2023/04/psychiatryai_com.webp)
Alzheimer’s disease biomarker analysis using targeted mass spectrometry
🌐 365 Days
AI Virtual Reality Related Evidence Matrix
Comparison of immunoassay- with mass spectrometry-derived p-tau quantification for the detection of Alzheimer's disease pathology An interim exploratory proteomics biomarker analysis of a phase 2 clinical trial to assess the impact of CT1812 in Alzheimer's disease Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease Distinct transcriptional alterations distinguish Lewy body disease from Alzheimer's disease Next-generation proteomics technologies in Alzheimer's disease: from clinical research to routine diagnostics Amyloid-β and Phosphorylated Tau are the Key Biomarkers and Predictors of Alzheimer's Disease Considerations for biomarker strategies in clinical trials investigating tau-targeting therapeutics for Alzheimer's disease Genomic stress and impaired DNA repair in Alzheimer disease Cerebrospinal fluid biomarker panel for synaptic dysfunction in a broad spectrum of neurodegenerative diseases Targeted examination of amyloid beta and tau protein accumulation via positron emission tomography for the differential diagnosis of Alzheimer's disease based on the A/T(N) research framework Phosphorylation-state dependent intraneuronal sorting of Aβ differentially impairs autophagy and the endo-lysosomal system Alzheimer Disease Biomarkers: Moving from CSF to Plasma for Reliable Detection of Amyloid and tau Pathology Microglia-astrocyte crosstalk in the amyloid plaque niche of an Alzheimer's disease mouse model, as revealed by spatial transcriptomics Serum GFAP levels correlate with astrocyte reactivity, post-mortem brain atrophy and neurofibrillary tangles Co-registration of MALDI-MSI and histology demonstrates gangliosides co-localize with amyloid beta plaques in Alzheimer's disease Co-registration of MALDI-MSI and histology demonstrates gangliosides co-localize with amyloid beta plaques in Alzheimer's disease Liver as a new target organ in Alzheimer's disease: insight from cholesterol metabolism and its role in amyloid-beta clearance Spatial Neurolipidomics at the Single Amyloid-β Plaque Level in Postmortem Human Alzheimer's Disease Brain In situ seeding assay: A novel technique for direct tissue localization of bioactive tau Integration of Microfluidic Devices with Microelectrode Arrays to Functionally Assay Amyloid-β-Induced Synaptotoxicity Multiple system atrophy with amyloid-b-predominant Alzheimer's disease neuropathologic change Navigating the Dementia Landscape: Biomarkers and Emerging Therapies Towards cascading genetic risk in Alzheimer's disease Personalized whole-brain neural mass models reveal combined Ab and tau hyperexcitable influences in Alzheimer's disease p-tau Ser356 is associated with Alzheimer's disease pathology and is lowered in brain slice cultures using the NUAK inhibitor WZ4003 Proteomic analysis of the human hippocampus identifies neuronal pentraxin 1 (NPTX1) as synapto-axonal target in late-stage Parkinson's disease CSF 14-3-3β is associated with progressive cognitive decline in Alzheimer's disease Blood Pressure Variability and Plasma Biomarkers of Neuronal Injury and Alzheimer's Disease: A Clinic-Based Study of Patients with Diseases Along the Heart-Brain Axis Plasma brain-derived tau is an amyloid-associated neurodegeneration biomarker in Alzheimer's disease Reactive astrocytes secrete the chaperone HSPB1 to mediate neuroprotection Induced pluripotent stem cell models as a tool to investigate and test fluid biomarkers in Alzheimer's disease and frontotemporal dementia CSF p-tau205: a biomarker of tau pathology in Alzheimer's disease Blood biomarkers open a window to brain pathophysiology in Alzheimer's disease CSF metabolites associated with biomarkers of Alzheimer's disease pathology Remodelling of the cardiac extracellular matrix proteome during chronological and pathological ageing Ischemia-Reperfusion Programming of Alzheimer's Disease-Related Genes-A New Perspective on Brain Neurodegeneration after Cardiac Arrest Neuropathology of Alzheimer's Disease Proteomics Impact on Cell Biology to Resolve Cell Structure and Function Senile plaque-associated transactive response DNA-binding protein 43 in Alzheimer's disease: A case report spanning 16 years of memory loss Spatial transcriptomic patterns underlying amyloid-β and tau pathology are associated with cognitive dysfunction in Alzheimer's disease Cerebrospinal fluid biomarkers and cognitive trajectories in patients with Alzheimer's disease and a history of traumatic brain injury Validating blood tests as a possible routine diagnostic assay of Alzheimer's disease Role of PIM Kinase Inhibitor in the Treatment of Alzheimer's Disease Passive tau-based immunotherapy for tauopathies Fe65-engineered neuronal exosomes encapsulating corynoxine-B ameliorate cognition and pathology of Alzheimer's disease Blood-Based Biomarkers for Early Alzheimer's Disease Diagnosis in Real-World Settings Human iPSC-derived retinal organoids develop robust Alzheimer's disease neuropathology Proteomic analysis of P. gingivalis-Lipopolysaccharide induced neuroinflammation in SH-SY5Y and HMC3 cells Biomarkers associated with the pathogenesis of Alzheimer's disease Evaluation of SP3 for antibody-free quantification of tau in CSF mimic and brain by mass spectrometry Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation Large-scale proteomics analysis of five brain regions from Parkinson's disease patients with a GBA1 mutation Resiliency to Alzheimer's disease neuropathology can be distinguished from dementia using cortical astrogliosis imaging Neuropsychiatric Symptoms and Microglial Activation in Patients with Alzheimer Disease Plasma p-tau212: antemortem diagnostic performance and prediction of autopsy verification of Alzheimer's disease neuropathology The Biochemistry Behind Cognitive Decline: Biomarkers of Alzheimer's Disease P2Y1 receptor in Alzheimer's disease Blood-based biomarkers in Alzheimer's disease - moving towards a new era of diagnostics Memantine versus Ginkgo biloba Extract: A Comparative Study on Cognitive Dysfunction Treatment in a Novel Rat Model Brain vasculature accumulates tau and is spatially related to tau tangle pathology in Alzheimer's disease Characteristics of discordance between amyloid positron emission tomography and plasma amyloid-β 42/40 positivity Downregulation of Dickkopf-3, a Wnt antagonist elevated in Alzheimer's disease, restores synapse integrity and memory in a disease mouse model Characterization of reduced astrocyte creatine kinase levels in Alzheimer's disease Modern neurophysiological techniques indexing normal or abnormal brain aging